Checkpoint Inhibition in Lymphoma

Abstract: Checkpoint inhibition improves surveillance by the immune system and therefore outcomes in some lymphoma subtypes. In this review, we examine the available evidence regarding […]

A Closer Look at Copanlisib

Copanlisib (Aliqopa, Bayer HealthCare) received accelerated approval on September 14, 2017, for the treatment of adults with relapsed follicular lymphoma who have received at least 2 […]

Advances in the Management of Primary Mediastinal Large B-Cell Lymphoma

H&O What is primary mediastinal large B-cell lymphoma? RA Primary mediastinal large B-cell lymphoma is a subtype of diffuse large B-cell lymphoma that is more […]

Advances in the Management of Primary Central Nervous System Lymphoma

H&O What is primary CNS lymphoma? KD Primary central nervous system (CNS) lymphoma is a subtype of diffuse large B-cell lymphoma (DLBCL), the most common […]

The Use of CAR T Cells in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

H&O Why are new treatments needed in DLBCL and MCL? PM Existing therapies are ineffective in a subset of patients or have toxicities that make […]

Natural Killer/T-Cell Lymphomas in Pediatric and Adolescent Patients

Abstract: Natural killer/T-cell (NK/T-cell) lymphomas are rare in children and adolescents and consist predominantly of nasal-type extranodal NK/T-cell lymphomas. More than half of pediatric/adolescent patients […]

An Interim Analysis of the ZUMA-1 Study of KTE-C19 in Refractory, Aggressive Non-Hodgkin Lymphoma

H&O What are the current treatment approaches for patients with refractory aggressive DLBCL? SN The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL) is […]

Aggressive B-Cell Lymphoma: The Double-Hit and Double-Expressor Phenotypes

H&O What are some recent developments in the understanding of genetics in aggressive B-cell lymphoma? SS There are between 60 and 80 different types of […]